Table 1.

Comparison of baseline variables for allopurinol and febuxostat.

VariablesAllopurinol, n = 102Febuxostat, n = 32p
Age, yrs47.9 (11.9)51.5 (14.1)0.157
Male100 (98)32 (100)1.00
BMI, kg/m2, median (IQR)*27 (25–29), n = 8828 (26–32), n = 310.202
Referred for gout65 (63.7)18 (56.2)0.447
Comorbidity18 (19.1)16 (50)0.562
  Hypertension42 (41.2)16 (22.9)0.379
  Diabetes mellitus14 (13.7)2 (6.2)0.356
  Renal insufficiency12 (11.8)1 (3.1)0.189
  Hyperlipidemia25 (25)9 (28.1)0.725
  Alcohol intake0.556
    None25 (24.5)9 (28.1)
    < 50 g/week72 (70.6)20 (62.5)
    > 50 g/week5 (4.9)3 (9.4)
FLD severity0.853
  Mild42 (41.2)13 (40.6)
  Moderate42 (41.2)12 (37.5)
  Severe18 (17.6)7 (21.9)
Laboratory data
  ALT, IU/l, median (IQR)34 (27–44)64.5 (27–78.8)0.257
  AST, IU/l, median (IQR)45 (31–63.3)41.5 (26.5.3–51)0.411
  ALP, IU/l, median (IQR)71 (59–89.5)67.5 (55.3–83.3)0.321
  Bilirubin, IU/l, median (IQR)0.8 (0.7–1.1)0.8 (0.6–0.9)0.151
  GFR, ml/min/1.73 m28.3 (1.8), n = 9988.1 (16.8)0.294
  Uric acid, mg/dl*83.8 (20.9)8.6 (1.4)0.299
  • Values are mean (SD) unless otherwise specified.

  • * Missing values were excluded from analysis. BMI: body mass index; IQR: interquartile range; FLD: fatty liver disease; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; GFR, glomerular filtration rate.